Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLNO Soleno Therapeutics

Trading 03-24 15:44:59 EDT

31.18

-0.54

-1.70%

High31.44	Low30.11	Vol1.65M
Open31.31	D1 Closing31.72	Amplitude4.18%
Mkt Cap1.61B	Tradable Cap1.40B	Total Shares51.62M
T/O50.71M	T/O Rate3.67%	Tradable Shares44.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":31.18,"timestamp":1774381498216,"preClose":31.72,"halted":0,"volume":1646598,"delay":0,"changeRate":-0.01702395964691044,"floatShares":44870900,"shares":51624384,"eps":0.39,"marketStatus":"Trading","change":-0.54,"latestTime":"03-24 15:44:59 EDT","open":31.31,"high":31.435,"low":30.11,"amount":50708847.712338,"amplitude":0.041772,"askPrice":31.2,"askSize":584,"bidPrice":31.13,"bidSize":404,"shortable":3,"etf":0,"ttmEps":0.39,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774382400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":31.72,"preHourTrading":{"tag":"盘前","latestPrice":31,"preClose":31.72,"latestTime":"09:29 EDT","volume":3335,"amount":106016.61515000001,"timestamp":1774358997027,"change":-0.72,"changeRate":-0.022699,"amplitude":0.126103},"postHourTrading":{"tag":"盘后","latestPrice":31.73,"preClose":31.72,"latestTime":"19:52 EDT","volume":17978,"amount":570398.77,"timestamp":1774309969890,"change":0.01,"changeRate":0.000315,"amplitude":0.000315},"volumeRatio":1.396995,"impliedVol":0.9821,"impliedVolPercentile":0.8167},"requestUrl":"/m/hq/s/SLNO","defaultTab":"news","newsList":[{"id":"2621770927","title":"Soleno Therapeutics Faces Investor Lawsuit Over Alleged Safety Concealment in VYKAT XR Drug Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770927","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770927?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:39","pubTimestamp":1774273191,"startTime":"0","endTime":"0","summary":"Soleno (SLNO) promoted VYKAT XR as the first approved treatment for hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder. Com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/soleno-therapeutics-faces-investor-lawsuit-over-alleged-safety-concealment-in-vykat-xr-drug-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/soleno-therapeutics-faces-investor-lawsuit-over-alleged-safety-concealment-in-vykat-xr-drug-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2620022210","title":"Class Action Lawsuit Targets Soleno Therapeutics Over Alleged Securities Law Violations","url":"https://stock-news.laohu8.com/highlight/detail?id=2620022210","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620022210?lang=en_us&edition=fundamental","pubTime":"2026-03-20 00:01","pubTimestamp":1773936093,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit was filed against Soleno and certain officers over alleged federal securities law violations.The suit covers investors who purchased or acquired Soleno securities between March 26, 2025 and November 4, 2025.The complaint alleges Soleno downplayed or concealed safety concerns in its Phase 3 program for DCCR, including excess fluid retention in trial participants.Claims also include that DCCR’s safety risks and commercial viability were materially worse than disclosed.Investors have until May 5, 2026 to seek appointment as lead plaintiff.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL80HXms:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014021.USD","SG9999014013.SGD","BK4112","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4588","SLNO","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2W23.USD","BK4585","SG9999014005.SGD","BK4139","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2620826304","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2620826304","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620826304?lang=en_us&edition=fundamental","pubTime":"2026-03-19 01:16","pubTimestamp":1773854172,"startTime":"0","endTime":"0","summary":"Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF  each falling 1.2%.The iShares Biotechnology ETF  dropped 1.6%.In corporate news, Soleno Therapeutics  is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note. Oppenheimer reiterated its outperform rating on Soleno Therapeutics, while cutting the company's price target to $80 from $110. Soleno shares were down 1%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","BK4588","SLNO","BK4581","LABU","XBI","XLV","BK4585","BK4139"],"gpt_icon":0},{"id":"2620268920","title":"Soleno Therapeutics Is Maintained at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620268920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620268920?lang=en_us&edition=fundamental","pubTime":"2026-03-19 00:17","pubTimestamp":1773850620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 12:17 ET (16:17 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","SLNO"],"gpt_icon":0},{"id":"2620509902","title":"Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2620509902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620509902?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:32","pubTimestamp":1773847941,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics  is expected to see a slower US launch for Vykat XR, but 2026 sales could still beat expectations, Oppenheimer said in a note Wednesday.Vykat XR targets Prader-Willi syndrome, a rare condition characterized by excessive desire to eat, or hyperphagia, which is the major source of morbidity and mortality, the note said.The firm said it now expects US sales of $491 million in 2026, $620 million in 2027, $725 million in 2028, $819 million in 2029, and $901 million in 2030, down from Oppenheimer's previous estimates of $563 million, $827 million, $1.2 billion, $1.44 billion, and $1.57 billion, respectively.The firm added that while it expects a seasonal impact to Q1, the current market expectations are \"conservative.\" It projects the quarter's revenue to be $97 million, with optimism for a stronger start to the year.Oppenheimer reiterated its outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110.Price: 33.10, Change: -0.52, Percent Change","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLNO","OPY"],"gpt_icon":0},{"id":"2620258053","title":"Soleno Therapeutics price target lowered to $80 from $110 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258053?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:45","pubTimestamp":1773834340,"startTime":"0","endTime":"0","summary":"Oppenheimer lowered the firm’s price target on Soleno Therapeutics (SLNO) to $80 from $110 and keeps an Outperform rating on the shares. The firm h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-80-from-110-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-80-from-110-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO","OPY"],"gpt_icon":0},{"id":"2620283593","title":"Soleno Therapeutics publishes corporate presentation on VYKAT XR launch and USD 190.4 million sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2620283593","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620283593?lang=en_us&edition=fundamental","pubTime":"2026-03-18 10:44","pubTimestamp":1773801889,"startTime":"0","endTime":"0","summary":"Soleno said VYKAT XR was approved by the FDA in March 2025 for hyperphagia in adults and pediatric patients aged 4 years and older with Prader-Willi syndrome. The company reported net revenue of USD 190.4 million for the year ended Dec. 31, 2025, and cash of USD 506.1 million at Dec. 31, 2025. Soleno also reported positive net income of USD 20.9 million for the year ended Dec. 31, 2025. Launch metrics cited include 859 active patients and a discontinuation rate due to adverse events of about 12% as of end of day Dec. 31, 2025. Soleno said it announced a USD 100 million stock repurchase in November 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2W2MwD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2619002466","title":"Soleno Therapeutics faces securities class action over DCCR safety disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2619002466","media":"Reuters","labels":["shareholding","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619002466?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:45","pubTimestamp":1773668725,"startTime":"0","endTime":"0","summary":"Investors filed a securities class action against Soleno and certain senior executives in the U.S. District Court for the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, No. 26-cv-01979. The suit covers purchases of Soleno common stock from March 26, 2025 to November 4, 2025 and alleges violations of the Securities Exchange Act of 1934. Plaintiffs allege the company downplayed or concealed safety concerns tied to DCCR, including excess fluid retention, affecting the drug’s risk profile and commercial viability. The filing cites a Scorpion Capital report followed by a stock decline of nearly 12% over two trading days. It also cites a disclosure of a patient death after taking DCCR, followed by an approximately 19% stock decline over two trading days, and later results citing launch disruption followed by an approximately 27% decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9WFxLr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2619665534","title":"Soleno Therapeutics adopts amended and restated bylaws effective March 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619665534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619665534?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:29","pubTimestamp":1773667756,"startTime":"0","endTime":"0","summary":"Soleno said its board approved and adopted amended and restated bylaws, effective March 16, 2026. The changes update advance notice provisions for stockholder proposals and director nominations. The amendments also reflect changes in Delaware law and include certain governance updates. Soleno said the bylaws add a forum selection provision and make technical and clarifying changes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL1M20hQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2619319747","title":"Cantor Fitzgerald Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619319747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619319747?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:45","pubTimestamp":1773405943,"startTime":"0","endTime":"0","summary":"In a report released today, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Soleno Therapeutics, with a price target of $123.00. A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-soleno-therapeutics-slno-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-soleno-therapeutics-slno-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2618502972","title":"Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2618502972","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618502972?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:54","pubTimestamp":1773273266,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets , including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL1Zlbdy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BGHQF748.EUR","NDAQ","SLNO","BK4112","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","BK4139","IE00B64PRP62.GBP","BK4585","BK4588"],"gpt_icon":0},{"id":"2618954051","title":"Soleno Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954051","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618954051?lang=en_us&edition=fundamental","pubTime":"2026-03-10 23:25","pubTimestamp":1773156344,"startTime":"0","endTime":"0","summary":"Meetings to be held in Chicago on March 10 and in Minneapolis on March 11 hosted by Piper Sandler. Published first on TheFly – the ultimate source ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2617567378","title":"Soleno Therapeutics Files Initial Beneficial Ownership Statement for CFO Jennifer Fulk","url":"https://stock-news.laohu8.com/highlight/detail?id=2617567378","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617567378?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:58","pubTimestamp":1772665133,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. filed an initial statement of beneficial ownership naming Jennifer Fulk, Chief Financial Officer, as the reporting person. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL3X6ztz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2616371515","title":"Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371515","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371515?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:16","pubTimestamp":1772626560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 07:16 ET (12:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"gpt_icon":0},{"id":"2616343515","title":"Soleno Therapeutics price target lowered to $100 from $120 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616343515","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616343515?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:10","pubTimestamp":1772622611,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $120 and keeps a Buy rating o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-100-from-120-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-100-from-120-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"1129164987","title":"Stock Track | Soleno Therapeutics Soars 5.43% in Post-Market Trading After Wells Fargo Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1129164987","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129164987?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:34","pubTimestamp":1772228081,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) experienced a significant surge of 5.43% in post-market trading on Friday. The after-hours movement followed the stock's regular session activity.The sharp increase appears...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLNO"],"gpt_icon":0},{"id":"2614686822","title":"Soleno Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2614686822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614686822?lang=en_us&edition=fundamental","pubTime":"2026-02-28 00:13","pubTimestamp":1772208780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 11:13 ET (16:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"gpt_icon":0},{"id":"2614855230","title":"Soleno Therapeutics price target lowered to $110 from $114 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2614855230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614855230?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:56","pubTimestamp":1772196983,"startTime":"0","endTime":"0","summary":"Wells Fargo lowered the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $114 and keeps an Overweight rating on the shares. While man...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-110-from-114-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-110-from-114-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2614886603","title":"Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886603","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886603?lang=en_us&edition=fundamental","pubTime":"2026-02-27 14:02","pubTimestamp":1772172125,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) has disclosed a new risk, in the Sales & Marketing category. Soleno Therapeutics has only recently begun generating prod...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-risky-bet-on-vykat-xr-commercial-regulatory-and-funding-hurdles-threaten-path-to-profitability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-risky-bet-on-vykat-xr-commercial-regulatory-and-funding-hurdles-threaten-path-to-profitability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"1146141276","title":"Stock Track | Soleno Therapeutics Plummets 11.88% After TD Cowen Slashes Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1146141276","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146141276?lang=en_us&edition=fundamental","pubTime":"2026-02-26 23:32","pubTimestamp":1772119979,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics' stock plunged 11.88% at the open on Thursday, as a significant analyst downgrade weighed heavily on investor sentiment.The sharp intraday decline followed news that TD Cowen cut...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLNO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":-0.05},{"period":"1month","weight":-0.1941},{"period":"3month","weight":-0.3505},{"period":"6month","weight":-0.5082},{"period":"1year","weight":-0.3541},{"period":"ytd","weight":-0.3149}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.026118},{"month":2,"riseRate":0.333333,"avgChangeRate":0.234502},{"month":3,"riseRate":0.583333,"avgChangeRate":-0.008565},{"month":4,"riseRate":0.454545,"avgChangeRate":0.050237},{"month":5,"riseRate":0.545455,"avgChangeRate":0.074125},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.071619},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.051924},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014863},{"month":9,"riseRate":0.454545,"avgChangeRate":0.409781},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.115533},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.012609},{"month":12,"riseRate":0.333333,"avgChangeRate":0.051862}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}